Antidepressant amitriptyline… Effective in secondary treatment according to Lancet
[의약뉴스]
Interesting clinical results have shown that an antidepressant treatment shows significant results in treating patients with Irritable Bowel Syndrome (IBS).
Irritable bowel syndrome is a common disease worldwide, with more than 1 million people diagnosed in Korea as of 2020.
According to data published in the medical journal the Lancet on the 16th, the antidepressant amitriptyline is effective in improving the symptoms of patients with irritable bowel syndrome.
The study was a randomized, double-blind, placebo-controlled trial involving 463 adult patients with irritable bowel syndrome at 55 general medical centers in the UK. Patients received either low-dose amitriptyline (10 mg once daily, 232 patients) for 6 months. Placebo (231 people) was administered.
▲ A treatment for depression is attracting attention as it has been shown to be effective in improving irritable bowel symptoms.
Age 18 or older, meets the criteria for any type of Rome IV IBS, and has persistent symptoms despite dietary control and primary treatment with a score of 75 or higher (IBS Severity Scoring System) [IBS-SSS] score ≥75 points) and those with blood count and C-reactive protein within the normal range participated in the clinical trial.
As a result of the phase 3 clinical analysis, low-dose amitriptyline showed a significant difference compared to placebo in IBS-SSS scores between the two groups at 6 months (–27·0, 95% CI –46·9 to –7·10; p= 0·0079).
There were 46 (20%) participants who discontinued low-dose amitriptyline 6 months ago, of which 30 (13%) discontinued due to side effects, and 59 (26%) participants discontinued placebo. Of these, 20 (9%) discontinued due to side effects.
Two cases of serious side effects occurred in the low-dose amitriptyline group and three cases in the placebo group, and five cases of serious side effects unrelated to the clinical trial drug were found.
The researchers explained that this trial is the largest-scale trial of tricyclic antidepressants for irritable bowel syndrome, and added that appropriate low-dose amitriptyline should be provided to patients with irritable bowel syndrome whose symptoms have not improved with first-line treatment.
Copyright © Medicine News. Reproduction and redistribution prohibited.
2023-10-17 08:49:31
#depression #treatment #option #patients #irritable #bowel #syndrome
